Core Viewpoint - Recent clinical research on Yuan Da Pharmaceutical's product Qino (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in evidence-based medicine for the product [1][3]. Group 1: Clinical Research and Product Validation - The study, led by Professor Wang Dehui from Fudan University, involved over 300 patients across 13 major hospitals in China and demonstrated the safety and efficacy of Qino when used in conjunction with Budesonide nasal spray [4][5]. - Results indicated that the combination therapy significantly improved symptom scores and control rates compared to the control group, particularly in patients with a history of smoking [5][7]. - This research fills a gap in evidence for long-term combination therapy, supporting Qino's inclusion in standardized treatment pathways for chronic rhinosinusitis [7]. Group 2: Market Position and Growth Potential - Qino is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its clinical significance and market leadership in cough and phlegm relief [4][10]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7]. - Yuan Da Pharmaceutical has a diverse product pipeline addressing various respiratory conditions, including asthma and chronic obstructive pulmonary disease, enhancing its competitive edge in the market [11][12]. Group 3: Future Development and Strategic Focus - The company emphasizes innovation and advanced technology in product development, aiming to create a comprehensive management product cluster for chronic respiratory diseases and critical care [16]. - Yuan Da Pharmaceutical's strategic focus on both domestic and international markets is expected to strengthen its industry position and drive valuation growth [15].

Core Viewpoint - YuanDa Pharmaceutical (00512) is deepening its strategy in urological diagnosis and treatment products, aiming to unlock a market potential worth billions through strategic investments in the urology field [1][3]. Group 1: Strategic Cooperation - The company has signed a cooperation agreement with Shanghai Yingte Weilu Medical Device Co., Ltd. to obtain global exclusive commercialization rights for the VTAS steam ablation product for treating benign prostatic hyperplasia (BPH) [1]. - This strategic cooperation aligns with YuanDa's dual focus on "products" and "technology," creating a new pattern of "channel expansion" and "innovation collaboration" [3]. - The partnership will accelerate market penetration post-product launch and enhance the research collaboration, solidifying YuanDa's global strategic layout in the urology diagnosis and treatment sector [3][12]. Group 2: Market Potential and Technology - BPH is a common urological condition among middle-aged and elderly men, with a prevalence rate of 60% in men over 60 and up to 90% in those aged 70-80, affecting over 100 million men in China [4]. - Traditional treatment methods include medication and invasive surgeries, which have limitations such as impact on sexual function and surgical risks [4][5]. - The steam ablation technology offers a minimally invasive solution, with advantages such as short operation time (under 10 minutes), low recurrence rates, and high safety, making it a promising alternative in the BPH treatment landscape [6][7]. Group 3: Product Features and Innovations - The VTAS steam ablation system is the only BPH steam ablation product in China with a core patent for steam generation and control, enhancing treatment efficacy and safety [6]. - VTAS features advanced energy control precision, stable steam output, and a unique puncture structure design ensuring 100% puncture success [6][7]. - The product is compatible with most bladder scopes and incorporates self-developed algorithms and AI-assisted functions for personalized treatment [7]. Group 4: Broader Product Ecosystem - YuanDa has developed a comprehensive product cluster in the urology field, covering various conditions including urinary tract cancer and prostate cancer, enhancing its market control [8]. - The company holds exclusive commercialization rights for several innovative products, including early detection tools for urinary tract cancer, which have received breakthrough device designation from the FDA [8][9]. - YuanDa's Go Global strategy aims to establish a global pharmaceutical brand, leveraging its full industry chain capabilities in the nuclear medicine and high-end medical device sectors [12].

Core Viewpoint - The company is deepening its strategic investment in urology treatment products, aiming to tap into a market potential worth billions through a partnership with Shanghai Yingtai Weilu Medical Device Co., Ltd. [1][3] Group 1: Strategic Partnership - The collaboration with Shanghai Yingtai Weilu Medical Device Co., Ltd. grants the company exclusive global commercialization rights for the VTAS steam ablation product, designed for treating benign prostatic hyperplasia (BPH) [1][3] - The partnership will establish a joint laboratory to enhance drug-device research and development, expanding the company's industrial ecosystem [1][3] Group 2: Market Potential and Treatment Landscape - BPH is a common urological condition among middle-aged and elderly men, with over 100 million men in China affected, and the prevalence increases with age [4][6] - Traditional treatment methods include medication and invasive surgeries, which have various drawbacks such as impact on sexual function and surgical risks [4][5] Group 3: Advantages of VTAS Technology - The VTAS steam ablation technology offers significant advantages, including a short operation time of under 10 minutes, minimal invasiveness, and a lower recurrence rate, making it a promising alternative to traditional treatments [6][7] - The product features unique technology with a patented steam generation and control method, ensuring high precision and stability in treatment [6][7] Group 4: Comprehensive Product Portfolio - The company has developed a diverse product portfolio in the urology field, covering various conditions including urinary tract cancer and prostate cancer, enhancing its market competitiveness [8][9] - The company holds exclusive commercialization rights for several innovative products, including early detection tools for urinary tract cancer, which have received breakthrough device designation from the FDA [9][10] Group 5: Global Expansion Strategy - The company is committed to a "Go Global" strategy, aiming to establish a global pharmaceutical brand by leveraging its comprehensive capabilities across the entire supply chain [10][13] - The establishment of a joint laboratory is expected to enhance the company's competitive edge in the urology product sector and drive long-term innovation [12][13]

Core Viewpoint - The Hong Kong International Biotechnology Forum and Exhibition (BIOHK) 2025 serves as a significant platform for industry leaders to discuss the future of biotechnology, with a focus on the global strategy of the pharmaceutical company YuanDa Pharmaceutical [1][3]. Group 1: Company Strategy and Globalization - YuanDa Pharmaceutical is recognized as a leading global player in nuclear medicine, sharing its global strategy at the BIOHK 2025 forum [3][6]. - The company is implementing a "Go Global" strategy, focusing on global research, production, and sales to enhance the value of innovative products [3][10]. - YuanDa has achieved significant milestones in its nuclear medicine development, with its product Yttrium-90 microsphere injection being used in over 150,000 patients across more than 50 countries [6][10]. Group 2: Product Development and Market Expansion - The company has received CE mark certification for new indications of its innovative product, expanding its treatment scope to include multiple types of liver cancer, which is expected to double its market potential [6][10]. - YuanDa is advancing its pipeline with 15 innovative products in development, covering various cancers and utilizing five types of radioactive isotopes [7][9]. - The company is actively pursuing a "dual filing" strategy in the U.S. and China, with several products entering international Phase III clinical trials [9][10]. Group 3: Research and Production Capabilities - YuanDa has established a comprehensive global network for nuclear medicine, with research and production bases in Boston and Chengdu, and a sales network covering over 50 countries [11][13]. - The company has built a state-of-the-art production facility in Chengdu, recognized as one of the most automated and comprehensive nuclear medicine factories globally [11][13]. - YuanDa's global innovation strategy includes five research platforms and eight research centers, with a robust pipeline of 133 projects in various stages of development [13].

Core Viewpoint - The Hong Kong International Biotechnology Forum and Exhibition (BIOHK) 2025 serves as a significant platform for industry leaders to discuss the future of biotechnology, with a focus on the global strategy of Yuan Da Pharmaceutical in nuclear medicine [1][3]. Group 1: Company Strategy - Yuan Da Pharmaceutical is recognized as a leading global nuclear medicine company, sharing its unique global development strategy at the forum [3][5]. - The company is implementing a "Go Global" strategy, focusing on global R&D, production, and sales to enhance the long-term value of innovative products [3][5][9]. Group 2: Market Expansion - The recognition of Chinese innovative drugs is increasing globally, with a notable rise in the number of oral presentations by Chinese pharmaceutical companies at the ASCO conference, from 25 in 2023 to 84 in 2025 [3]. - In the first half of 2025, the transaction value of innovative drug licensing exceeded the total for 2024, indicating strong innovation capabilities [3]. Group 3: Product Development - Yuan Da Pharmaceutical has achieved significant breakthroughs in nuclear medicine, with its innovative product, Yttrium-90 microsphere injection, being used in over 50 countries and for more than 150,000 patients [5]. - The product is the first and only FDA-approved treatment for unresectable hepatocellular carcinoma (HCC) and colorectal cancer liver metastases, recently receiving CE mark certification for additional indications [5]. Group 4: R&D Pipeline - The company has 15 innovative products in the R&D registration phase, utilizing five types of radioactive isotopes to target eight different cancers [6][8]. - Yuan Da is advancing its "dual filing" strategy in the U.S. and China, with several products entering international multi-center Phase III clinical trials [8]. Group 5: Global Infrastructure - Yuan Da Pharmaceutical has established a comprehensive global sales network covering over 50 countries, supported by R&D bases in Boston and Chengdu, and production facilities in multiple international locations [10][12]. - The company’s Chengdu facility is noted for being one of the most automated and comprehensive nuclear medicine production plants globally, ensuring high-quality product supply [10]. Group 6: Long-term Vision - The company aims to deepen its global market penetration and brand development through its ongoing "Go Global" strategy, addressing unmet medical needs worldwide [12].

Core Viewpoint - The approval of the Blue Whale TM intracranial aneurysm embolization support frame marks a significant advancement in treatment options for intracranial aneurysms in China, enhancing the company's position in the high-end medical device market [1] Group 1: Company Developments - The company has been deeply engaged in the high-end medical device sector for many years, focusing on "precision treatment" and has established a comprehensive layout around three main areas: pathway management, structural heart disease, and heart failure [1] - The company has over 30 products in its high-end medical device portfolio, with 23 products approved for market in China under the pathway management category and 1 product approved for structural heart disease [1] - The company is actively advancing clinical registration for other products in China, with plans for phased and tiered launches of innovative products to drive stable growth in this business segment [1] Group 2: Global Expansion - The company is also expanding its global footprint in the field of cardiovascular precision interventional diagnosis and treatment, having established technical collaborations with clinical centers or R&D platforms in multiple countries including the USA, Canada, Germany, Italy, and Switzerland [1] - The company has successfully built a comprehensive "passive + active" innovative device platform, which is expected to enhance its capabilities in the global market [1] - With the ongoing implementation of its "Go Global" strategy, the company aims to develop this segment into a leading global platform for cardiovascular precision interventional diagnosis and treatment, further enhancing its overall value [1]

近日，远大医药(00512)颅内动脉瘤辅助栓塞支架蓝鲸TM获国家药监局批准上市(国械注准20253131589)。据悉，蓝鲸TM是我国国产首款编织型动脉瘤辅助 栓塞支架，不仅丰富了远大医药心脑血管精准介入诊疗领域的产品种类，更凸显出公司前瞻性布局的成效，同时也将为我国颅内动脉瘤治疗带来全新的治疗 选择。 国产首款编织型动脉瘤辅助栓塞支架，性能优越惠及千万患者 颅内动脉瘤作为脑内"不定时炸弹"，是引发脑出血的最常见原因，且一旦出血破裂致死率极高。《颅内动脉瘤显微手术治疗专家共识(2025版)》数据显示， 我国颅内动脉瘤的总体患病率达1.3%-7.6%，我国35-75岁人群的未破裂颅内动脉瘤的患病率约为7%，其破裂导致的动脉瘤性蛛网膜下腔出血在30天内的病 死率更是高达43%。据弗若斯特沙利文数据，我国颅内未破裂动脉瘤患病人数预计将于2028年增长至8,951.4万人。 据灼识咨询报告，2020年我国神经介入手术量约为16.14万台，预计将以28.6%的年复合增长率增长至74.05万台。在手术量的大幅增加下，神经介入医疗器 械的市场规模也正不断扩容，预计将在2026年增长至175亿元。 庞大的患者数字背后，是巨大 ...

智通财经APP获悉，近日，远大医药(00512)颅内动脉瘤辅助栓塞支架蓝鲸TM获国家药监局批准上市(国械注准20253131589)。据悉，蓝鲸TM是我国国产首 款编织型动脉瘤辅助栓塞支架，不仅丰富了远大医药心脑血管精准介入诊疗领域的产品种类，更凸显出公司前瞻性布局的成效，同时也将为我国颅内动脉瘤 治疗带来全新的治疗选择。 国产首款编织型动脉瘤辅助栓塞支架，性能优越惠及千万患者 具体而言，蓝鲸TM采用了独特的编织设计以及显影技术提供了一定程度的血流分流，以实现大于95%的血管造影动脉瘤闭塞。蓝鲸TM辅助支架全系列为镍 钛单丝16头编织设计，显著提升支架径向支撑及血管贴壁。此外，蓝鲸TM全系80%可回收释放，实现了可控输送和精准植入。基于独特coil缠绕显影技术等 多方面临床优势，蓝鲸TM颅内动脉瘤辅助栓塞支架未来有望使更多患者得到更为精准的颅内动脉瘤介入治疗方案，未来市场潜力十分可观。 前瞻布局百亿神经介入器械市场，打造高端器械产品集群 据灼识咨询报告，2020年我国神经介入手术量约为16.14万台，预计将以28.6%的年复合增长率增长至74.05万台。在手术量的大幅增加下，神经介入医疗器 械的市场规模也正不 ...

易甘泰自中国获批上市后快速放量，截至2024年末，该产品已累计治疗近2000例患者，2024年实现近5 亿港元销售收入，同比增速超140%。 远大医药在核药抗肿瘤诊疗板块已实现了研发、生产、配送、销售等多个环节的全方位布局，以波士 顿、成都为核心的研发基地，波士顿、法兰克福、新加波、成都所在的生产基地以及覆盖全球50多个国 家和地区的销售网络为基础，已实现全球化的核药产业链布局。 公司位于中国四川省成都市温江区的远大医药放射性药物研发及生产基地已于2025年6月底正式投入运 营。该基地覆盖"同位素制备-核药研发-生产临床-商业化"全链条，形成从早期研发到临床转化到上市销 售的全生命周期管理能力，14条高标准GMP生产线实现多品种、规模化制备需求。 中证报中证网讯(王珞)远大医药9月8日晚公告称，公司创新放射性产品SIR-Spheres钇[90Y]微球注射液 (易甘泰)近日在欧洲获批新适应症的CE标志认证，用于肝癌患者治疗。此次批准新增适应症使该疗法的 适用范围在原有的不可切除肝细胞癌(HCC)和不可切除结直肠癌肝转移(mCRC)的基础上，扩展到不可 切除肝内胆管癌(ICC)、神经内分泌瘤引起的肝转移(mNET ...

来源：环球网 远大医药核药"Go Global"战略再获重磅进展。 在取得亮眼的商业化成绩的同时，远大医药也在积极拓展钇[90Y]微球注射液在全球解锁更多的适应 症。今年7月，基于DOORwaY90临床试验的突破性中期数据，美国FDA提前正式批准钇[90Y]微球注射 液新增适应症，用于不可切除HCC，且未限制肿瘤直径大小，该产品成为全球首个且唯一获FDA批准 用于不可切除HCC和结直肠癌肝转移双重适应症的选择性内放射治疗产品。DOORwaY90中期临床结果 显示，钇[90Y]微球注射液治疗不可切除HCC的客观缓解率高达98.5%；所有可评估患者均显示治疗反 应，提示局部肿瘤控制率达到100%；此外，中位缓解持续时间超过300天。 适应症的持续拓展不仅为易甘泰®注入了全新的增长动力，更使其以"一药多能"的特性构建起管线级价 值，相当于以单产品之力实现了多产品管线的治疗覆盖，真正达成"一个产品匹敌一个管线"的战略突 破。 伴随着适应症范围的显著扩大，钇[90Y]微球注射液的适用患者将有望成倍增加，市场空间将实现战略 级的扩增，将开启"泛癌种治疗"新阶段。同时，接连取得的海外注册里程碑也彰显了远大医药优秀的海 外临 ...